CJC-1295 (DAC)

CJC-1295 (DAC) Overview

CJC-1295 (DAC) is a modified analogue of growth hormone-releasing hormone designed for prolonged activity. In research settings, it is used to examine sustained GHRH receptor signaling and the downstream endocrine pathways associated with extended peptide half-life. The “DAC” component refers to the drug affinity complex that allows the peptide to bind endogenous albumin and remain active longer than the non-DAC form.

Mechanism of Action & Applications

CJC-1295 (DAC) is studied for agonist activity at the GHRH receptor. Its DAC modification enables covalent binding to circulating albumin, which extends its half-life and makes it useful in research involving prolonged receptor stimulation, pituitary signaling, and hormone-release dynamics. It is commonly studied in models involving GHRH receptor biology, growth hormone pathway signaling, peptide half-life extension, and albumin-binding peptide design.

Research History

CJC-1295 (DAC) emerged from efforts to create a longer-acting GHRH analogue with improved stability and duration. Published work in the mid-2000s described it as a modified GHRH-based peptide capable of prolonged biological activity through albumin conjugation, distinguishing it from shorter-acting GHRH analogues and from CJC-1295 without DAC.

Chemical Information

CAS Number

446262-90-4

Molecular Formula

C₁₆₅H₂₆₉N₄₇O₄₆

Molecular Weight

3,647.2 g/mol

PubChem ID

56841945